Cargando…
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicity of classic chemotherapy agents. These drugs have been extensively studied both in solid and hematolo...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Exploration
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400759/ https://www.ncbi.nlm.nih.gov/pubmed/36046840 http://dx.doi.org/10.37349/etat.2022.00077 |